Get started
Work

Evaluation of the Comparative Effectiveness of Labetolol and Methyldopa in the Treatment of Pregnancy Induced Hypertension

Year: 2025
Type: article
Abstract: Objective: To compare effectiveness of labetolol and methyldopa in the treatment of pregnancy induced hypertension. Methods: This randomized controlled trial was carried out in the Obstetrics & Gynaecology Department at a Tertiary Care Hospital in Rahim Yar Khan from September 2022 to March 2023. The study involved a total of 84 patients, with 42 patients in each group (Labetalol and Methyldopa). Inclusion criteria encompassed patients aged 20 to 40 years, with gestational age ≥ 20 weeks, and diagnosed with Pregnancy induced hypertension (PIH). The study aimed to compare the effectiveness of Labetalol and Methyldopa in treating PIH. Results: The mean age for the Labetalol group is 29.48 with a standard deviation (SD) of 6.500, while the Methyldopa group has a mean age of 31.55 with an SD of 5.844. The mean gestational age for the Labetalol group is 28.38 weeks with an SD of 4.732, and for the Methyldopa group, it is 29.64 weeks with an SD of 4.509. In the Labetalol group, 38 out of 42 patients (90.5%) experienced efficacy, compared to 30 out of 42 (71.4%) in the Methyldopa group. The P-value of 0.049 suggests that the difference in efficacy between the both study groups is statistically significant, favouring Labetalol as the more effective treatment for pregnancy-induced hypertension. Conclusion: Our study strongly suggests that Labetalol is more effective than Methyldopa in treating pregnancy-induced hypertension, particularly in older age groups. Future research is needed to explore side-effect profiles for a comprehensive understanding.
DOI: 10.70302/jpsim.v6i1.2509
Authors: Umber Imtiaz Khan, Syeda Uzma, Zubaida Shaheen, Sadia Ghaffar, Faria Mumtaz, Javaria Nosheen
Language: English
Field: Medicine
Open Access status: hybrid
OpenAlex ID: W4408373955
FWCI:
Cites:
Cited by:
Related to: 10